Media Release Ypsomed focuses on growth and strengthens its business units Burgdorf, 23.02.2022, 7.00 a.m. – With the aim of focusing on changing customer needs, Ypsomed is stepwise optimizing the organisation of the business units and the Management Board. Ypsomed places emphasis on more agile business units to successfully achieve planned growth Agility is essential for success in the global market. The game-changing digitisation in healthcare and the associated combination of high-quality products into connected therapy management solutions for improved therapy outcomes calls for closer cooperation between marketing and product development. Ypsomed is therefore merging these areas into the respective operational business units Ypsomed Delivery Systems (YDS) and Ypsomed Diabetes Care (YDC), which now bear responsibility for results from the concept through to sales, by September 2022. This enables to anticipate market and customer requirements more quickly and shortens the time to market for new products and solutions. Streamlined structures and processes will also ensure increased effectiveness and efficiency. In this context, Hans Ulrich Lehmann, who has been CTO and a member of the Management Board since 2011, will assume responsibility for the high-growth product area of autoinjectors in the YDS business unit as of September. His responsibilities will include the further development of the autoinjector family and ensuring outstanding services for pharmaceutical customers.
Ypsomed is thus gradually laying the organisational foundations for sustainable growth by autumn 2022 and will continue to invest heavily in research and development as well as in personnel expansion in the future. Sébastien Delarive to become new Senior Vice President Diabetes Care Sébastien Delarive will succeed Dr Eberhard Bauer, who is going to retire after ten years at Ypsomed, by June 2022. Under Eberhard Bauer's leadership, Ypsomed made a comeback in the pump business, introduced the mylife OmniPod and the mylife YpsoPump system outside the USA and successively expanded the country subsidiaries. 52-year-old Delarive draws on more than 25 years of experience from various positions in international marketing, sales, product lifecycle and general management in the pharmaceutical and medical technology sectors. In his most recent position as of Head of Europe he was responsible for the General Medicine business area at Sanofi. The native Swiss started his career in sales at Astra and Biokema. He later joined the pharmaceutical company Sanofi, where he held various management positions in France, Scandinavia, the USA, Japan and Latin America. Sébastien Delarive studied chemistry at the ETH Lausanne (EPFL). "I am delighted that Sébastien Delarive, an internationally experienced manager, has accepted the position for our Diabetes Care business unit. In addition to developing the mylife YpsoPump system further, his tasks will focus specifically on clearly aligning the organisation with the market", comments Simon Michel, CEO, on the strengthening of the management team. Sébastien Delarive - High resolution image | 
